- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2015
- Public Summary Document (PSD) November 2015 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2015 PBAC Meeting - Word
Adalimumab – November 2015
Adalimumab: 40 mg/0.8 mL injection, 2 x 0.8 mL cartridges; 40 mg/0.8 mL injection, 2 x 0.8 mL syringes; 40 mg/0.8 mL injection, 6 x 0.8 mL cartridges;40 mg/0.8 mL injection, 6 x 0.8 mL syringes, Humira®
Last updated
4 March 2016
